drugset
drugset / Trial / NCT05021328

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NCT05021328 ↗

Phase 1 Completed 13 enrolled Hubei Cancer Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the efficacy and safety of toripalimab combined with anlotinib and SBRT for non-driver gene mutation untreated brain metastases non-small Cell Lung Cancer.

Timeline

Start
2021-10-01
Primary completion
2025-02-05
Completion
2025-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

non-small cell lung carcinoma